Lilly, Incyte rheumatoid arthritis drug succeeds.
|
5:01:00 AM |
No Comments |
Eli Lilly and Co and Incyte Corp said a third late-stage study of their experimental rheumatoid arthritis drug met its main goal.
The drug, baricitinib, was more effective than the decades-old treatment methotrexate, after 24 weeks of treatment, in reducing signs and symptoms of the inflammatory disorder, the companies said on Tuesday.
